Literature DB >> 22415521

Growth assays to assess polyglutamine toxicity in yeast.

Martin L Duennwald1.   

Abstract

Protein misfolding is associated with many human diseases, particularly neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Huntington's disease (HD) is caused by the abnormal expansion of a polyglutamine (polyQ) region within the protein huntingtin. The polyQ-expanded huntingtin protein attains an aberrant conformation (i.e. it misfolds) and causes cellular toxicity. At least eight further neurodegenerative diseases are caused by polyQ-expansions, including the Spinocerebellar Ataxias and Kennedy's disease. The model organism yeast has facilitated significant insights into the cellular and molecular basis of polyQ-toxicity, including the impact of intra- and inter-molecular factors of polyQ-toxicity, and the identification of cellular pathways that are impaired in cells expressing polyQ-expansion proteins. Importantly, many aspects of polyQ-toxicity that were found in yeast were reproduced in other experimental systems and to some extent in samples from HD patients, thus demonstrating the significance of the yeast model for the discovery of basic mechanisms underpinning polyQ-toxicity. A direct and relatively simple way to determine polyQ-toxicity in yeast is to measure growth defects of yeast cells expressing polyQ-expansion proteins. This manuscript describes three complementary experimental approaches to determine polyQ-toxicity in yeast by measuring the growth of yeast cells expressing polyQ-expansion proteins. The first two experimental approaches monitor yeast growth on plates, the third approach monitors the growth of liquid yeast cultures using the BioscreenC instrument. Furthermore, this manuscript describes experimental difficulties that can occur when handling yeast polyQ models and outlines strategies that will help to avoid or minimize these difficulties. The protocols described here can be used to identify and to characterize genetic pathways and small molecules that modulate polyQ-toxicity. Moreover, the described assays may serve as templates for accurate analyses of the toxicity caused by other disease-associated misfolded proteins in yeast models.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22415521      PMCID: PMC3460590          DOI: 10.3791/3461

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  14 in total

1.  Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains.

Authors:  Anatoli B Meriin; XiaoQian Zhang; Ilya M Alexandrov; Alexandra B Salnikova; Michael D Ter-Avanesian; Yury O Chernoff; Michael Y Sherman
Journal:  FASEB J       Date:  2007-03-06       Impact factor: 5.191

Review 2.  Screening for genetic modifiers of amyloid toxicity in yeast.

Authors:  Flaviano Giorgini; Paul J Muchowski
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

3.  Flanking sequences profoundly alter polyglutamine toxicity in yeast.

Authors:  Martin L Duennwald; Smitha Jagadish; Paul J Muchowski; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-10       Impact factor: 11.205

4.  A network of protein interactions determines polyglutamine toxicity.

Authors:  Martin L Duennwald; Smitha Jagadish; Flaviano Giorgini; Paul J Muchowski; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-10       Impact factor: 11.205

5.  A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.

Authors:  Flaviano Giorgini; Paolo Guidetti; QuangVu Nguyen; Simone C Bennett; Paul J Muchowski
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

6.  A chaperone pathway in protein disaggregation. Hsp26 alters the nature of protein aggregates to facilitate reactivation by Hsp104.

Authors:  Anil G Cashikar; Martin Duennwald; Susan L Lindquist
Journal:  J Biol Chem       Date:  2005-04-20       Impact factor: 5.157

Review 7.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

Review 8.  Glutamine repeats and neurodegeneration.

Authors:  H Y Zoghbi; H T Orr
Journal:  Annu Rev Neurosci       Date:  2000       Impact factor: 12.449

Review 9.  Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease?

Authors:  Aaron D Gitler
Journal:  Neurosignals       Date:  2007-12-05

10.  Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1.

Authors:  Anatoli B Meriin; Xiaoqian Zhang; Xiangwei He; Gary P Newnam; Yury O Chernoff; Michael Y Sherman
Journal:  J Cell Biol       Date:  2002-06-10       Impact factor: 10.539

View more
  2 in total

1.  Growth-based determination and biochemical confirmation of genetic requirements for protein degradation in Saccharomyces cerevisiae.

Authors:  Sheldon G Watts; Justin J Crowder; Samuel Z Coffey; Eric M Rubenstein
Journal:  J Vis Exp       Date:  2015-02-16       Impact factor: 1.355

2.  A Liquid to Solid Phase Transition Underlying Pathological Huntingtin Exon1 Aggregation.

Authors:  Thomas R Peskett; Frédérique Rau; Jonathan O'Driscoll; Rickie Patani; Alan R Lowe; Helen R Saibil
Journal:  Mol Cell       Date:  2018-05-10       Impact factor: 17.970

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.